These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

558 related articles for article (PubMed ID: 26397223)

  • 1. BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells.
    Ambrosini G; Sawle AD; Musi E; Schwartz GK
    Oncotarget; 2015 Oct; 6(32):33397-409. PubMed ID: 26397223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells.
    Musi E; Ambrosini G; de Stanchina E; Schwartz GK
    Mol Cancer Ther; 2014 May; 13(5):1044-53. PubMed ID: 24563540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chloroquine Sensitizes
    Truong A; Yoo JH; Scherzer MT; Sanchez JMS; Dale KJ; Kinsey CG; Richards JR; Shin D; Ghazi PC; Onken MD; Blumer KJ; Odelberg SJ; McMahon M
    Clin Cancer Res; 2020 Dec; 26(23):6374-6386. PubMed ID: 32933997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of chromosomal aberrations and GNAQ, GNA11 and BAP1 mutations in uveal melanoma.
    Staby KM; Gravdal K; Mørk SJ; Heegaard S; Vintermyr OK; Krohn J
    Acta Ophthalmol; 2018 Feb; 96(1):31-38. PubMed ID: 28444874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.
    Chen X; Wu Q; Tan L; Porter D; Jager MJ; Emery C; Bastian BC
    Oncogene; 2014 Sep; 33(39):4724-34. PubMed ID: 24141786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting primary and metastatic uveal melanoma with a G protein inhibitor.
    Onken MD; Makepeace CM; Kaltenbronn KM; Choi J; Hernandez-Aya L; Weilbaecher KN; Piggott KD; Rao PK; Yuede CM; Dixon AJ; Osei-Owusu P; Cooper JA; Blumer KJ
    J Biol Chem; 2021; 296():100403. PubMed ID: 33577798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.
    Ambrosini G; Pratilas CA; Qin LX; Tadi M; Surriga O; Carvajal RD; Schwartz GK
    Clin Cancer Res; 2012 Jul; 18(13):3552-61. PubMed ID: 22550165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.
    Wu X; Li J; Zhu M; Fletcher JA; Hodi FS
    Mol Cancer Ther; 2012 Sep; 11(9):1905-14. PubMed ID: 22653968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uveal melanoma driver mutations in GNAQ/11 yield numerous changes in melanocyte biology.
    Perez DE; Henle AM; Amsterdam A; Hagen HR; Lees JA
    Pigment Cell Melanoma Res; 2018 Sep; 31(5):604-613. PubMed ID: 29570931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Digital PCR validates 8q dosage as prognostic tool in uveal melanoma.
    Versluis M; de Lange MJ; van Pelt SI; Ruivenkamp CA; Kroes WG; Cao J; Jager MJ; Luyten GP; van der Velden PA
    PLoS One; 2015; 10(3):e0116371. PubMed ID: 25764247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reciprocal positive regulation between BRD4 and YAP in GNAQ-mutant uveal melanoma cells confers sensitivity to BET inhibitors.
    Zhang GM; Huang SS; Ye LX; Liu XL; Shi WH; Ren ZL; Zhou RH; Zhang JJ; Pan JX; Liu SW; Yu L; Li YL
    Pharmacol Res; 2022 Oct; 184():106464. PubMed ID: 36162600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.
    Wu X; Zhu M; Fletcher JA; Giobbie-Hurder A; Hodi FS
    PLoS One; 2012; 7(1):e29622. PubMed ID: 22253748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequent and Yet Unreported GNAQ and GNA11 Mutations are Found in Uveal Melanomas.
    Schneider B; Riedel K; Zhivov A; Huehns M; Zettl H; Guthoff RF; Jünemann A; Erbersdobler A; Zimpfer A
    Pathol Oncol Res; 2019 Oct; 25(4):1319-1325. PubMed ID: 29209985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Uveal Melanoma: Molecular and Genetic Mechanisms of Development and Therapeutic Approaches].
    Zhilnikova MV; Troitskaya OS; Novak DD; Atamanov VV; Koval OA
    Mol Biol (Mosk); 2024; 58(2):189-203. PubMed ID: 39355878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Copper ionophore elesclomol selectively targets GNAQ/11-mutant uveal melanoma.
    Li Y; Yang J; Zhang Q; Xu S; Sun W; Ge S; Xu X; Jager MJ; Jia R; Zhang J; Fan X
    Oncogene; 2022 Jul; 41(27):3539-3553. PubMed ID: 35697803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma.
    Chen X; Wu Q; Depeille P; Chen P; Thornton S; Kalirai H; Coupland SE; Roose JP; Bastian BC
    Cancer Cell; 2017 May; 31(5):685-696.e6. PubMed ID: 28486107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uveal Melanoma:
    Psinakis F; Katseli A; Koutsandrea C; Frangia K; Florentin L; Apostolopoulou D; Dimakopoulou K; Papakonstantinou D; Georgopoulou E; Brouzas D
    Anticancer Res; 2017 Oct; 37(10):5719-5726. PubMed ID: 28982892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneity in Mitogen-Activated Protein Kinase (MAPK) Pathway Activation in Uveal Melanoma With Somatic GNAQ and GNA11 Mutations.
    Boru G; Cebulla CM; Sample KM; Massengill JB; Davidorf FH; Abdel-Rahman MH
    Invest Ophthalmol Vis Sci; 2019 Jun; 60(7):2474-2480. PubMed ID: 31173078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GNAQ/11 mutations in uveal melanoma: is YAP the key to targeted therapy?
    Field MG; Harbour JW
    Cancer Cell; 2014 Jun; 25(6):714-5. PubMed ID: 24937456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chromosome 3 status combined with BAP1 and EIF1AX mutation profiles are associated with metastasis in uveal melanoma.
    Ewens KG; Kanetsky PA; Richards-Yutz J; Purrazzella J; Shields CL; Ganguly T; Ganguly A
    Invest Ophthalmol Vis Sci; 2014 Jun; 55(8):5160-7. PubMed ID: 24970262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.